Akums Drugs & Pharmaceuticals Ltd.

Akums’ new medicine will be sold for sickle cell disease treatment. Credit: kikpokemon / Shutterstock.com. Indian company Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, the country’s first room temperature-stable drug for treating sickle cell disease, according to a LinkedIn post . The new formulation offers a cost-effective alternative to imported brands in the country. Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy. The existing imported Hydroxyurea solution, which requires refrigeration between 2°C and 8°C, costs Rs77,000 ($928.9) in the Indian market. Akums’ novel oral suspension drug will be available for Rs600, making it highly accessible to patients. See Also: With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline An inherited blood ailment, sickle cell disease changes the red blood cells into a sickle shape, which hampers their ability to transport oxygen across the body effectively. Hydroxyurea aids red blood cells to maintain a rounder and larger shape, allowing for improved oxygen delivery throughout the body. In a media statement posted on LinkedIn, Akums Drugs and Pharmaceuticals said: “In alignment with the objectives outlined in the national sickle cell anaemia mission, as announced by the Honourable Prime Minister Shri Narendra Modi Ji, Akums pledges to provide this medicine to the government at less than 1% of the cost of global brand imported in India, thus embodying the spirit of ‘Make in India’ and fostering widespread benefit to the masses.”

NEW YORK, Jan. 17, 2024 /PRNewswire/ -- The over-the-counter (OTC) analgesics market is expected to grow by USD 6.52 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 4.74% during the forecast period, according to Technavio Research. The market is segmented by type (internal and external), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 42% to the growth of the global market during the forecast period. The growth of the North American OTC analgesics market is notably driven by several key factors, including a rise in healthcare expenditure, a high prevalence of pain-related conditions and arthritis, the robust presence of vendors within the region, and supportive government policies. Continue Reading Technavio has announced its latest market research report titled Global Over the Counter (OTC) Analgesics Market 2023-2027 This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read the Free PDF Sample Report Company Profile: AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cardinal Health Inc., Cipla Ltd., CV Sciences Inc., Endo International Plc, GlaxoSmithKline Plc, Medterra CBD, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group Plc, Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Weefsel Pharma, and AKUMS Bayer AG: The company offers over the counter analgesics used for chronic pain and migraine. To gain access to more company profiles available with Technavio, buy the report! Over The Counter (OTC) Analgesics Market: Segmentation Analysis By Segment - The market share growth by the internal segment is significant during the forecast period. Internal analgesics primarily serve the purpose of internal use and can be administered orally in the form of pills and liquids or inserted rectally in suppository form. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Over The Counter (OTC) Analgesics Market: Driver & Trend: Growing aging population globally Increasing prevalence of pain-related conditions Growing number of mergers and acquisitions (M&A) activities The growing aging population across the world drives the market growth. The global demographic landscape is undergoing a noteworthy transformation, primarily driven by the growing aging population, which is a significant contributor to market growth. The Over-the-Counter (OTC) Analgesics Market faces the challenge of balancing consumer healthcare needs with safety and side effects, particularly concerning Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like Ibuprofen, Naproxen, and Aspirin, as well as Acetaminophen (Paracetamol). Innovations in product forms such as gel capsules, effervescent tablets, and topical analgesics, including pain relief creams, offer varied options for pain management, from migraine relief to menstrual and muscle pain relief, and solutions for arthritis pain and fever reducers. However, the rise in self-medication trends, influenced by consumer preferences and pain management education, intensifies the need for a stringent regulatory framework. This includes overseeing the prescription to OTC switch and monitoring analgesic combinations. The market also sees a shift towards herbal and natural remedies, challenging traditional OTC analgesic brands. Adult analgesics and pediatric pain relievers must adapt to these shifts. Moreover, the expansion of distribution channels from drugstore chains to online pharmacies requires innovative packaging solutions and accurate market forecasting. This dynamic market landscape demands a balance between meeting consumer health needs and ensuring responsible use of OTC analgesics. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information. Related Reports: The renal anemia therapeutics market size is estimated to grow by USD 2.08 billion, at a CAGR of 7.59% between 2023 and 2028. The equine supplement products market size is estimated to grow by USD 20,352.14 at a CAGR of 4.19% between 2023 and 2028. What are the key data covered in this over the counter (OTC) analgesics market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the over the counter (OTC) analgesics market between 2022 and 2027. Precise estimation of the over the counter (OTC) analgesics market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the over the counter (OTC) analgesics market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of over the counter (OTC) analgesics market players. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Type Market Segmentation by Distribution Channel Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Over the past year and a half, Congress has provided $178 billion to support healthcare providers amid the Covid-19 pandemic, but billions still remain unspent, according to a new report by the Robert Wood Johnson Foundation. Specifically, there was around $26.8 billion left unspent in the Provider Relief Fund in October, of which $11.7 billion has been allocated but not spent, $7.1 billion has not been allocated and $8 billion has been returned. Prepared by researchers at the Urban Institute with funding from the Robert Wood Johnson Foundation, the report used the most recent publicly available information to review how grants from the Provider Relief Fund have been allocated into general and targeted distributions and paid to providers. Starting in April 2020, the Department for Health and Human Services released funds in two categories — one was general distribution and the other was targeted distributions to certain providers, including safety-net hospitals, rural providers and skilled nursing homes. But, as of February, providers had returned $8 billion of the funds they received. Nearly three-quarters of the returned grants were from the general distributions, $2 billion from high-impact grants — that is, funds provided to hospitals in areas hit hardest by the pandemic at the time — and $1 billion from other targeted distributions. Among the organizations that returned the funds were several major nonprofit and for-profit health systems that reported “they did not need the money because they had gained experience managing operations and expenses as the pandemic progressed, or they recovered sooner than expected,” the report states. Organizations that have returned funds include Oakland, California-based Kaiser Permanente that returned $500 million and Nashville, Tennessee-based HCA Healthcare that gave back a whopping $1.6 billion. Though some providers have returned the money, others have asked for more time to spend it. Providers currently have about a year from when they received the funds to spend it or they must return the money. The American Hospital Association is continuing to press HHS to let providers keep the money through the end of the public health emergency. Report authors expect the Provider Relief Fund’s balance to increase as several facilities will need to return some of the grants because they cannot meet HHS’ timelines for usage. Moving forward, policymakers must consider how best to financially support providers as the pandemic drags on. “As the pandemic persists, we now have greatly improved knowledge of how to treat patients with Covid-19 and also a better understanding of how providers have used (or returned) emergency grants,” said Teresa A. Coughlin, a senior fellow at the Urban Institute, in an emailed news release. “Policymakers have an opportunity to consider how best to target the remaining funds in the Covid-19 Provider Relief Fund to healthcare providers to support providers who have been hardest hit by the pandemic and continue to have the greatest needs.”